Synergy Pharmaceuticals Inc. (SGYP) Major Shareholder Paulson & Co. Inc. Sells 3,473,713 Shares
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) major shareholder Paulson & Co. Inc. sold 3,473,713 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $5.61, for a total value of $19,487,529.93. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) opened at 5.55 on Wednesday. Synergy Pharmaceuticals Inc. has a 52-week low of $2.50 and a 52-week high of $7.15. The firm’s 50-day moving average price is $4.92 and its 200-day moving average price is $3.82. The stock’s market cap is $995.93 million.
Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. Equities analysts predict that Synergy Pharmaceuticals Inc. will post ($1.03) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/synergy-pharmaceuticals-inc-sgyp-major-shareholder-paulson-co-inc-sells-3473713-shares.html
Several institutional investors have recently added to or reduced their stakes in SGYP. Paulson & CO. Inc. increased its position in Synergy Pharmaceuticals by 150.3% in the second quarter. Paulson & CO. Inc. now owns 27,756,668 shares of the biopharmaceutical company’s stock worth $105,475,000 after buying an additional 16,666,668 shares in the last quarter. Vanguard Group Inc. increased its position in Synergy Pharmaceuticals by 80.8% in the second quarter. Vanguard Group Inc. now owns 12,309,494 shares of the biopharmaceutical company’s stock worth $46,775,000 after buying an additional 5,500,297 shares in the last quarter. BlackRock Fund Advisors increased its position in Synergy Pharmaceuticals by 54.7% in the second quarter. BlackRock Fund Advisors now owns 8,824,549 shares of the biopharmaceutical company’s stock worth $33,533,000 after buying an additional 3,120,748 shares in the last quarter. State Street Corp increased its position in Synergy Pharmaceuticals by 41.3% in the second quarter. State Street Corp now owns 5,182,008 shares of the biopharmaceutical company’s stock worth $19,689,000 after buying an additional 1,515,232 shares in the last quarter. Finally, Societe Generale acquired a new position in Synergy Pharmaceuticals during the second quarter worth about $4,729,000. Hedge funds and other institutional investors own 56.67% of the company’s stock.
SGYP has been the topic of several recent research reports. BTIG Research restated a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a research report on Friday, September 16th. HC Wainwright set a $15.00 target price on Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, September 8th. Rodman & Renshaw reiterated a “buy” rating and issued a $15.00 price objective on shares of Synergy Pharmaceuticals in a research report on Thursday, September 8th. Canaccord Genuity reiterated a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Sunday, July 17th. Finally, Roth Capital reiterated a “buy” rating and issued a $6.50 price objective on shares of Synergy Pharmaceuticals in a research report on Thursday, May 26th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.75.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.